CNS Response, a provider of reference data and analytic tools for clinicians and researchers in psychiatry, today announced that the U.S. Food and Drug Administration (FDA) has responded to the company’s proposal for a clinical trial of an investigational device, PEER Interactive, designed to help physicians identify the best treatments for certain mental illnesses.
PEER Interactive, a Web service based on a standard electroencephalogram (EEG), records a patient’s brain function much like an electrocardiogram (EKG) does for the heart. The Psychiatric EEG Evaluation Registry (PEER) was developed by physicians as a quality assurance tool to determine which psychiatric medications are effective and which are not.
In its response, the FDA acknowledged that PEER Interactive would require pre-market approval, though the agency indicated that under certain circumstances the product could shift to the 510(k) pathway.
In regards to the FDA’s additional comments and suggestions, CNS said it will revise its protocol to implement the FDA’s suggestions, and that it will launch a clinical trial with Walter Reed National Military Medical Center (WRNMMC) and several other sites to establish partnerships with military physicians to diagnose mental health conditions such as depression, post-traumatic stress disorder (PTSD), mild traumatic brain injury (mTBI), and several other disorders.
The WRNMMC has indicated that it will lead the study upon approval of the final protocol.
The company also highlighted the following studies conducted within the last year:
• INSURANCE STUDY: An audit of commercial health plan enrollees which found a 71 percent improvement in outcomes for physicians using PEER; an 85 percent reduction in suicidality; and successful prediction of severe adverse events in 55 percent of cases.
• DEPRESSION STUDY: A 12-week study of treatment-resistant depression, in which physicians achieved a 65 percent success rate in treating patients with depression, compared to a 39 percent success rate in the control group.
• EATING DISORDERS: A retrospective study of eating disorder patients with comorbid major depression or bipolar disorder. Physicians demonstrated that using PEER data helped reduce trial and error medication selection, and significantly decreased patient symptoms of depression, and reduced overall hospitalization days by 53 percent.
• ADHD: Recent studies demonstrate a dramatic increase in medication use for ADHD, without corresponding improvements in outcomes. A Michigan State study demonstrated that 1 million children — of the 4.5 million currently diagnosed with ADHD — may be misdiagnosed.
For more information visit www.cnsresponse.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment